相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Hypoxia-inducible factor 2α: a novel target in gliomas
Jaclyn J. Renfrow et al.
FUTURE MEDICINAL CHEMISTRY (2018)
Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells
Nicole Colwell et al.
NEURO-ONCOLOGY (2017)
Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy
Tianchi Yu et al.
YONSEI MEDICAL JOURNAL (2017)
The Role of Hypoxia in Glioblastoma Invasion
Ana Rita Monteiro et al.
CELLS (2017)
Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy
Sergio Rey et al.
TRENDS IN CANCER (2017)
HIF-1 in cancer therapy: two decade long story of a transcription factor
Sourabh Soni et al.
ACTA ONCOLOGICA (2017)
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
Eli M. Wallace et al.
CANCER RESEARCH (2016)
Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model
Gina Lee et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Simultaneous targeting of Eph receptors in glioblastoma
Sara Ferluga et al.
ONCOTARGET (2016)
A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.
Kevin Dale Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Causal analysis approaches in Ingenuity Pathway Analysis
Andreas Kraemer et al.
BIOINFORMATICS (2014)
Transcriptional regulation by hypoxia inducible factors
Veronica L. Dengler et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2014)
Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors
William H. Gmeiner et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Normalization of RNA-seq data using factor analysis of control genes or samples
Davide Risso et al.
NATURE BIOTECHNOLOGY (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
RNA-SeQC: RNA-seq metrics for quality control and process optimization
David S. DeLuca et al.
BIOINFORMATICS (2012)
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors
Yan Xia et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2012)
Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas
Yuka Yamamoto et al.
NUCLEAR MEDICINE COMMUNICATIONS (2012)
HIF1 alpha and HIF2 alpha: sibling rivalry in hypoxic tumour growth and progression
Brian Keith et al.
NATURE REVIEWS CANCER (2012)
GC-Content Normalization for RNA-Seq Data
Davide Risso et al.
BMC BIOINFORMATICS (2011)
Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors
Xing-gang Mao et al.
LABORATORY INVESTIGATION (2011)
Differential activation and antagonistic function of HIF-α isoforms in macrophages are essential for NO homeostasis
Norihiko Takeda et al.
GENES & DEVELOPMENT (2010)
Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
Tomoko Ozawa et al.
Jove-Journal of Visualized Experiments (2010)
Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells
Zhizhong Li et al.
CANCER CELL (2009)
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype
John M. Heddleston et al.
CELL CYCLE (2009)
Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor
Thomas H. Scheuermann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
Sith Sathornsumetee et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy
Eduard B. Dinca et al.
JOURNAL OF NEUROSURGERY (2007)
'Pseudopalisading' necrosis in glioblastoma: A familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis
Yuan Rong et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2006)
EphA2 as a novel molecular marker and target in glioblastoma multiforme
J Wykosky et al.
MOLECULAR CANCER RESEARCH (2005)
Hypoxia-induced dedifferentiation of tumor cells -: A mechanism behind heterogeneity and aggressiveness of solid tumors
H Axelson et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Structural basis for PAS domain heterodimerization in the basic helix-loop-helix-PAS transcription factor hypoxia-inducible factor
PJA Erbel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Inhibition of HIF2 alpha is sufficient to suppress pVHL-defective tumor growth
K Kondo et al.
PLOS BIOLOGY (2003)
The fibroblast growth factor receptor is at the site of convergence between μ-opioid receptor and growth factor signaling pathways in rat C6 glioma cells
MM Belcheva et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Necrosis and glioblastoma: A friend or a foe? A review and a hypothesis
SA Raza et al.
NEUROSURGERY (2002)
Hypoxia - A key regulatory factor in tumour growth
AL Harris
NATURE REVIEWS CANCER (2002)
分享论文
